Bingyu Li

Dr. Bingyu Li

Pathology, Mount Sinai Health System, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
BLBingyu Li
Bingyu Li
QZQiong Zhang
Qiong Zhang
CCClaire Castaneda
Claire Castaneda
SCShelly M Cook
Shelly M Cook
Pancreatic ductal adenocarcinoma (PDAC), a leading cause of cancer mortality in the United States, presents significant treatment challenges due to its late diagnosis and poor prognosis. Despite advances, the five-year survival rates remain dismally low, with only a fraction of patients eligible for potentially curative surgical interventions. This review aims to comprehensively examine the current landscape of targeted therapies in PDAC, focusing on recent developments in precision medicine approaches. We explore various molecular targets, including KRAS mutations, DNA damage repair deficiencies, mismatch repair pathway alterations, and rare genetic fusions. The review discusses emerging therapies, such as PARP inhibitors, immune checkpoint inhibitors, and novel targeted agents, like RET and NTRK inhibitors. We analyze the results of key clinical trials and highlight the potential of these targeted approaches in specific patient subgroups. Recent developments in PDAC research have emphasized precision oncology, facilitated by next-generation sequencing and the identification of genetic and epigenetic alterations. This approach tailors treatments to individual genetic profiles, improving outcomes and reducing side effects. Significant strides have been made in classifying PDAC into various subtypes, enhancing therapeutic precision. The identification of specific mutations in genes like KRAS, along with advancements in targeted therapies, including small molecule inhibitors, offers new hope. Furthermore, emerging therapies targeting DNA repair pathways and immunotherapeutic strategies also show promising results. As research evolves, integrating these targeted therapies with conventional treatments might improve survival rates and quality of life for PDAC patients, underscoring the shift towards a more personalized treatment paradigm.

10 July 2021 in Rheumatology
Verified
Journal Article
Closed access
PDF file
LYLusi Ye
Lusi Ye
SMShouliang Miao
Shouliang Miao
QXQinqin Xiao
Qinqin Xiao
YLYuncai Liu
Yuncai Liu
HTHongyan Tang
Hongyan Tang
DCDan Chen
Dan Chen
Construct and validate a nomogram model integrating the radiomics features and the clinical risk factors to differentiating axial spondyloarthritis (axSpA) in low back pain patients undergone sacroiliac joint (SIJ)- magnetic resonance imaging (MRI). 638 patients confirmed as axSpA (n= 424) or non-axSpA (n = 214) who were randomly divided into training (n = 447) and validation cohorts (n = 191). Optimal radiomics signatures were constructed from the 3.0T SIJ-MRI using maximum relevance–minimum redundancy (mRMR) and the least absolute shrinkage and selection operator (LASSO) algorithm in the training cohort. We also included six clinical risk predictors to build clinical model. Incorporating the independent clinical factors and Rad-score, a nomogram model was constructed by multivariable logistic regression analysis. The performance of the clinical, Rad-score, and nomogram model were evaluated by ROC analysis, calibration curve and decision curve analysis (DCA). 1316 features were extracted and reduced to 15 features to build the Rad-score. The Rad-score allowed a good discrimination in the training (AUC, 0.82; 95% CI, 0.77-0.86) and the validation cohort (AUC, 0.82; 95% CI, 0.76-0.88). The clinical-radiomics nomogram model also showed favorable discrimination in the training (AUC, 0.90; 95% CI, 0.86-0.93) and the validation cohort (AUC, 0.90; 95% CI, 0.85-0.94). Calibration curves (p > 0.05) and DCA demonstrated the nomogram was useful for axSpA diagnosis in the clinical environment. The study proposed a radiomics model was able to separate axSpA and non-axSpA. The clinical-radiomics nomogram can increase the efficacy for differentiating axSpA, which might facilitate clinical decision-making process.

8 December 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
BLBo Li
Bo Li
ZLZhijun Lei
Zhijun Lei
YWYou Wu
You Wu
BLBingyu Li
Bingyu Li
MZMing Zhai
Ming Zhai
WPWenhui Peng
Wenhui Peng
Background: Serine proteinase inhibitor A3 (SERPINA3) has been discovered in the pathogenesis of many human diseases, but little is known about the role of SERPINA3 in coronary artery disease (CAD). Therefore, we aim to determine its relationship with CAD and its function in the pathogenesis of atherosclerosis.Methods: In total 86 patients with CAD and 64 patients with non-CAD were compared. The plasma SERPINA3 levels were measured using ELISA. Logistic regression analysis and receiver-operating characteristic (ROC) analysis were performed to illustrate the association between plasma SERPINA3 levels and CAD. In vitro, real-time PCR (RT-PCR) and immunofluorescence staining were used to determine the expression of SERPINA3 in atherosclerotic plaques and their component cells. Then rat aortic smooth muscle cells (RASMCs) were transfected with siRNA to knock down the expression of SERPINA3 and human umbilical vein endothelial cells (HUVECs) were stimulated by SERPINA3 protein. EdU assay and scratch assay were used for assessing the capability of proliferation and migration. The cell signaling pathway was evaluated by western blot and RT-PCR.Results: Patients with CAD [104.4(54.5–259.2) μg/mL] had higher levels of plasma SERPINA3 than non-CAD [65.3(47.5–137.3) μg/mL] (P = 0.004). After being fully adjusted, both log-transformed and tertiles of plasma SERPINA3 levels were significantly associated with CAD. While its diagnostic value was relatively low since the area under the ROC curve was 0.64 (95% CI: 0.55–0.73). Secreted SERPINA3 might increase the expression of inflammatory factors in HUVECs. Vascular smooth muscle cells had the highest SERPINA3 expression among the aorta compared to endothelial cells and inflammatory cells. The knockdown of SERPINA3 in RASMCs attenuated its proliferation and migration. The phosphorylated IκBα and its downstream pathway were inhibited when SERPINA3 was knocked down.Conclusions: Elevated plasma SERPINA3 levels were associated with CAD. SERPINA3 can increase inflammatory factors expression in HUVECs. It can regulate VSMCs proliferation, migration, and releasing of inflammatory factors through the NF-κB signaling pathway. Thus, SERPINA3 played a significant role in the pathogenesis of atherosclerosis.

11 February 2022 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
ZLZhijun Lei
Zhijun Lei
BLBingyu Li
Bingyu Li
BLBo Li
Bo Li
WPWenhui Peng
Wenhui Peng
Background: There is little evidence on left ventricular ejection fraction (LVEF) trajectories after ST-segment elevation myocardial infarction (STEMI). Aim: We aim to identify the LVEF trajectories after STEMI and explore their predictors and association with prognosis. Methods: This is a retrospective, observational study of STEMI patients. The LVEF trajectories were identified by the latent class trajectory model in patients with baseline LVEF < 50%. We used logistic regression analysis to investigate the predictors for LVEF trajectories. The Cox proportional hazard model was used to assess the impact of LVEF trajectories on prognosis. The primary outcomes were cardiovascular mortality and heart failure (HF) rehospitalization. Results: 572 of 1179 patients presented with baseline normal LVEF (≥ 50%) and 607 with baseline reduced LVEF (< 50%). Two distinct LVEF trajectories were identified in patients with baseline reduced LVEF: recovered LVEF group and persistently reduced LVEF group. Higher baseline LVEF, lower peak troponin T, non-anterior MI, and lower heart rates were all found to be independently associated with LVEF recovery. After multivariate adjustments, patients with persistently reduced LVEF experienced an increased risk of cardiovascular mortality (HR 7.49, 95% CI 1.94–28.87, P = 0.003) and HF rehospitalization (HR 3.54, 95% CI 1.56–8.06 P = 0.003) compared to patients with baseline normal LVEF. Patients with recovered LVEF, on the other hand, showed no significant risk of cardiovascular mortality and HF rehospitalization. Conclusion: Our study indicated two distinct LVEF trajectories after STEMI and that the persistently reduced LVEF trajectory was related to poor prognosis. In addition, several baseline characteristics can predict LVEF recovery.

12 August 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
SGShiyu Gong
Shiyu Gong
JZJian Zhou
Jian Zhou
BLBingyu Li
Bingyu Li
SKSheng Kang
Sheng Kang
XMXiaoye Ma
Xiaoye Ma
XZXumin Zhang
Xumin Zhang
Objective: The probability of late recurrent atrial fibrillation (AF) after radiofrequency ablation (RFA) has not yet been fully clarified. This study aims to study the association of left atrial appendage (LAA) morphology with AF recurrence after RFA.Methods: We retrospectively enrolled 84 patients (24 patients had persistent AF, 60 patients had paroxysmal AF) who underwent RFA in Shanghai East Hospital from June 2014 to May 2018. The mean follow-up of these patients was 618.6 days. According to preoperative transesophageal echocardiography (TEE), the morphology feature of LAA was classified and evaluated by two classification methods. The first method was divided into chicken-wing, windsock, cactus, and cauliflower, and the second method was divided into one lobe, two lobes, and multiple lobes. The correlation between morphological feature of LAA and the recurrence rate of AF after RFA was analyzed.Results: During follow-up, 12 patients (50%) and 10 patients (16.7%) had AF recurrence in persistent and paroxysmal AF, respectively. The LAA morphology was associated with the recurrence of AF after RFA with the chicken-wing highest recurrence risk (68.2%). The structure type of LAA was also related to the AF recurrence rate (p < 0.01). Compared with one lobe and multiple lobes, two lobes (recurrence, 47.6%) were more likely associated with the recurrence of AF (p < 0.02). Logistic regression analysis showed that the chicken-wing group had a higher risk of recurrence after RFA (OR = 8.13, p = 0.004), and the windsock group had a lower risk of recurrence (OR = 0.17, p = 0.002).Conclusion: The morphological feature of LAA is related to the recurrence risk of AF after RFA. LAA morphology assessment can predict the risk of AF recurrence.

25 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BLBingyu Li
Bingyu Li
LHLarry Huang
Larry Huang
JHJialing Huang
Jialing Huang
JLJianhong L. Li
Jianhong L. Li
Hepatocellular carcinoma (HCC) remains a global health challenge due to molecular heterogeneity and frequent delayed diagnosis. This comprehensive review synthesizes recent immunohistochemistry (IHC) advancements for HCC diagnosis, prognostication, and therapeutic prediction. We systematically evaluate conventional markers, such as hepatocyte paraffin 1 (HepPar1), arginase-1 (Arg-1), and glypican-3 (GPC3), as well as emerging biomarkers, detailing their diagnostic sensitivities and specificities in HCC with varied tumor differentiation. Prognostic immunostaining markers, such as Ki-67 proliferation index and vascular endothelial growth factor (VEGF) overexpression, correlate with reduced 5-year survival, while novel immune checkpoint IHC markers (PD-L1 and CTLA-4) predict response to immunotherapy, particularly in advanced HCC. This work provides evidence-based recommendations for optimizing IHC utilization in clinical practice while identifying knowledge gaps in biomarker validation and standardization.